

---

# Pharmaceutical Crystallography

## A Guide to Structure and Analysis

---

**Andrew Bond**

*University of Cambridge, UK*

*Email: [adb29@cam.ac.uk](mailto:adb29@cam.ac.uk)*



# Contents

---

<b>1</b>	<b>Pharmaceutical Solids</b>	<b>1</b>
1.1	Introduction	1
1.2	Classifying Pharmaceutical Solids: An Overview	2
1.3	Structural Classification: Crystalline and Amorphous Solids	4
1.4	Chemical Classification: Single- and Multi-component Solids	8
1.5	Classifying Pharmaceutical Solids: More Details	11
1.6	Summary of Key Points	15
	References	15
<hr/>		
<b>2</b>	<b>What Defines a Crystal?</b>	<b>16</b>
2.1	Introduction	16
2.2	Lattices	17
2.3	Unit Cells	20
2.4	Fractional Coordinates	23
2.5	Metric Properties	24
2.6	Summary of Key Points	24
2.7	Case Study: Mefenamic Acid	25
	Note	27
	References	27

Pharmaceutical Crystallography: A Guide to Structure and Analysis

By Andrew Bond

© Andrew Bond 2019

Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)

<b>3</b>	<b>Symmetry in Crystals</b>	<b>28</b>
3.1	Introduction	28
3.2	Point Symmetry Operations	29
3.3	Point Symmetry in Crystals	38
3.4	Space Symmetry Operations	40
3.5	Summary of Key Points	43
3.6	Case Study: Formoterol Fumarate Dihydrate	44
	Reference	47
<hr/>		
<b>4</b>	<b>Space Groups</b>	<b>48</b>
4.1	Introduction	48
4.2	General Concepts of Space Groups	49
4.3	Crystal Systems	54
4.4	Centred Unit Cells	56
4.5	Space Group Symbols	61
4.6	Other Classifications of Space Groups	62
4.7	Summary of Key Points	63
4.8	Case Study: The Monoclinic Form of Paracetamol (Acetaminophen)	64
	References	67
<hr/>		
<b>5</b>	<b>Planes and Crystal Morphology</b>	<b>68</b>
5.1	Introduction	68
5.2	Defining Planes in Crystals	69
5.3	Crystal Planes and Crystal Faces	74
5.4	Summary of Key Points	78
5.5	Case Study: BFDH Morphology of Famotidine Form A	78
	Reference	81
<hr/>		
<b>6</b>	<b>Crystal Structures and Diffraction Patterns</b>	<b>82</b>
6.1	Introduction	82
6.2	X-ray Diffraction	83

6.3	The Geometry of Diffraction from a Single Crystal	83
6.4	The Intensities of Diffraction from a Single Crystal	93
6.5	A Review	101
6.6	Summary of Key Points	102
6.7	Case Study: Ropivacaine Hydrochloride Form 2	103
	Reference	106
<hr/>		
<b>7</b>	<b>Symmetry in Diffraction Patterns</b>	<b>107</b>
7.1	Introduction	107
7.2	Symmetry in Diffraction Patterns	108
7.3	Centrosymmetric and Non-centrosymmetric Structures	116
7.4	Summary of Key Points	122
7.5	Case Study: Ropivacaine Hydrochloride Form 2 (Continued)	123
<hr/>		
<b>8</b>	<b>Single-crystal X-ray Diffraction (Part 1)</b>	<b>125</b>
8.1	Introduction	125
8.2	Overview of a Single-crystal X-ray Diffractometer	126
8.3	Setting Up the Analysis	131
8.4	Measuring the Geometry of Diffraction	135
8.5	Measuring Crystal Morphology	143
8.6	Summary of Key Points	144
8.7	Case Study: Aspirin Form I	145
	References	148
<hr/>		
<b>9</b>	<b>Single-crystal X-ray Diffraction (Part 2)</b>	<b>149</b>
9.1	Introduction	149
9.2	Measuring the Diffracted Intensities	150
9.3	Measure First, Analyse Later	160
9.4	What's the Outcome of a Single-crystal Data Collection?	161
9.5	Summary of Key Points	163
9.6	Case Study: Aspirin Form I (Continued)	165

<b>10</b>	<b>Powder X-ray Diffraction</b>	<b>168</b>
10.1	Introduction	168
10.2	Relating Powder Diffraction to Single-crystal Diffraction	169
10.3	Powder X-ray Diffraction Measurements	175
10.4	The Sample	184
10.5	Extracting Information from a PXRD Pattern	185
10.6	Summary of Key Points	189
10.7	Case Study: Celecoxib	190
	References	193
<hr/>		
<b>11</b>	<b>Solving X-ray Crystal Structures</b>	<b>194</b>
11.1	Introduction	194
11.2	Building the Electron Density From the Structure Factors	195
11.3	The Phase Problem	202
11.4	Structure Solution in Practice	206
11.5	Developing the Structure Model	207
11.6	Summary of Key Points	209
11.7	Case Study: Sulfathiazole	211
	References	213
<hr/>		
<b>12</b>	<b>Refining X-ray Crystal Structures</b>	<b>214</b>
12.1	Introduction	214
12.2	Structure Refinement in Theory	215
12.3	Structure Refinement in Practice	220
12.4	Absolute Structure	230
12.5	Summary of Key Points	231
12.6	Case Study: Sulfathiazole (Continued)	232
	References	235
<hr/>		
<b>13</b>	<b>Disorder and Twinning</b>	<b>236</b>
13.1	Introduction	236
13.2	Disorder	237

13.3	Solvent Masking	240
13.4	Twinning	244
13.5	Summary of Key Points	252
13.6	Case Study 1: Griseofulvin–Nitroethane (1 : 1)	252
13.7	Case Study 2: L-Aspartic Acid	255
	References	259
<hr/>		
14	Crystallographic Results	260
14.1	Introduction	260
14.2	Uncertainties	261
14.3	Interpreting Crystallographic Results	266
14.4	Reporting Crystallographic Results	278
14.5	Summary of Key Points	282
14.6	Case Study: Perindoprilat Monohydrate	283
	References	285
<hr/>		
	Subject Index	286